Nxera secures exclusive APAC rights to DMD drug Vamorolone in deal with Santhera

Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories

Halozyme and Takeda team up to transform Crohn’s and Colitis Therapy

The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab

Pulmocide halts Phase 3 trial of Opelconazole in severe lung infection

The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit

Nimbus Therapeutics and Eli Lilly team up on novel obesity therapy

The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases

Breakthrough in PsA: Taltz plus Zepbound show major gains for patients with obesity

This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures

GSK secures European nod for easier-to-use Shingrix prefilled syringe

The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration

GSK reports breakthrough results in chronic hepatitis B trials

Iksuda reports promising early results for HER2-targeted therapy in oesophageal cancer

The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2

Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis

The FDA designation follows visual-function results from the Phase 2 ACUITY trial

World First: Heart bypass without opening the chest achieved by NIH and Emory Team